Journal Article

Palivizumab Treatment of Respiratory Syncytial Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation

Flore Sicre de Fontbrune, Marie Robin, Raphael Porcher, Catherine Scieux, Régis Peffault de Latour, Christèle Ferry, Vanderson Rocha, Karim Boudjedir, Agnès Devergie, Anne Bergeron, Eliane Gluckman, Elie Azoulay, Jordane Lapalu, Gérard Socié and Patricia Ribaud

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 45, issue 8, pages 1019-1024
Published in print October 2007 | ISSN: 1058-4838
Published online October 2007 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/521912
Palivizumab Treatment of Respiratory Syncytial Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Among 40 allogeneic stem cell transplant recipients who developed symptomatic respiratory syncytial virus infection, including 22 patients with lower respiratory tract infection, 19 received palivizumab (9 of whom had upper respiratory tract disease). Palivizumab did not prevent progression to lower respiratory infection and had no impact on the overall survival rate.

Journal Article.  2254 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.